Nomura analyst Jialin Zhang notes that traders are seeking refuge in healthcare due to the sector's robust fundamentals after a period of heavy selling. This shift coincides with new measures from China’s commerce and finance ministries designed to attract foreign investment. The updated policy framework expands commercial insurance coverage for innovative drugs and widens retail access for foreign medicines, signaling a clear intent to keep the market open to international capital.

Confidence among investors is further bolstered by the strength of the domestic pipeline and recent corporate moves. Eli Lilly’s new $1.9 billion research partnership with Abbisko has provided a fresh catalyst for sector growth. Meanwhile, WuXi-affiliated firms—including WuXi Biologics and WuXi XDC—saw significant gains, reinforced by aggressive share buyback programs that reflect internal optimism. Citi analysts highlight that China’s innovative drug sector continues to advance at a competitive pace, maintaining strong momentum across the entire value chain.